A major new National Health Service (NHS) program will offer the Meningitis B (MenB) vaccine to around one million young people in England, being rolled out in response to a series of outbreaks that have taken a toll and raised concerns among health officials.The one-off vaccination campaign will target Year 13 students and young people aged under 25 who will start university or residential further education this autumn. Health authorities say the move is aimed at protecting those most at risk as they prepare to enter environments where the disease is more easily spread through close contact.The news follows a number of MenB outbreaks this year, including a major cluster in Kent that became the largest and fastest-growing outbreak of its kind ever recorded in the UK. The outbreak resulted in two deaths and more than 20 confirmed cases, with further clusters subsequently reported in areas including Reading and Dorset.
Meningitis B vaccination in the UK
The government’s decision comes after health experts found an increased risk of MenB infection among older teenagers and young adults, particularly those moving into university halls of residence, shared dormitories and other living settings.Close social contact is known to increase the risk of meningococcal disease transmission, making first-year college students one of the most vulnerable groups. According to the UK Health and Safety Authority (UKHSA), first-year university students are at significantly higher risk of MenB infection than young people who have not attended university.Health Minister James Murray said the latest outbreak may indicate a change in the way the disease affects young people. He said the government was taking immediate action to protect those most at risk while reviewing the long-term evidence.
MenB Vaccine Eligibility
Under the scheme, all Year 13 students in England are eligible, as well as young people under the age of 25 starting university or residential further education for the first time this autumn.The offer will include international students aged under 25 starting study in the UK. Eligible students will receive two doses of the MenB vaccine, called Bexsero, produced by GSK. Injectable doses must be at least 28 days apart to provide full protection.The first dose of the vaccine will begin on July 20, with the second dose scheduled for August. Students away for the summer can still get their second dose in September. Eligible young people will be contacted via the NHS app, text message, email or letter, while others can book an appointment directly through a participating pharmacy.
Meningitis B cases across the UK
Meningitis B is caused by group B meningococci and can lead to life-threatening illnesses including meningitis (inflammation of the protective membrane around the brain and spinal cord) and sepsis (a serious blood infection that can develop into sepsis).Symptoms can develop rapidly and may include fever, severe headache, vomiting, drowsiness, sensitivity to light, difficulty breathing, and a distinctive rash that does not resolve under stress. Even with treatment, the disease can cause permanent disability, neurological damage, or death.Although the MenB vaccine has been routinely given to infants in the UK since 2015, most teenagers and young adults are too old to be vaccinated as part of the childhood programme, leaving a large number of the population without direct protection against this strain.The rollout of the vaccination program came under intense scrutiny of the UK’s MenB strategy following an outbreak centered in Kent earlier this year.Health officials say the speed of the Kent cluster is unprecedented. More than 20 infections have been linked to the outbreak, and two young people died after becoming infected. The outbreak triggered emergency vaccination campaigns, antibiotic distribution and calls from affected families for wider access to the MenB vaccine.The family of one of those who died, 18-year-old Juliette Kenny, later launched a campaign to expand vaccination coverage for teenagers and young adults. The outbreak has also raised new questions about whether MenB vaccination should be part of routine immunization schedules for adolescents.Further clusters of MenB cases have since emerged in Dorset and Reading, fueling concerns among public health officials that younger people may be at greater risk of the disease.
Looking to the future
The new rollout is currently a one-off emergency scheme rather than a permanent expansion of the NHS vaccination programme.However, the Joint Committee on Vaccination and Immunization (JCVI) is reviewing the latest evidence and is expected to advise ministers on whether a wider, long-term MenB vaccination program should be rolled out for adolescents.For now, health officials are urging eligible students to get two doses of the vaccine before the start of the school year, warning that early protection may help prevent further outbreaks of meningococcal disease when it typically peaks in the fall.
